Pfizer Announces Real-World Evidence Confirming Paxlovid Reduces COVID-19 Hospitalization Risk

Pfizer Inc. today announced new real-world evidence confirming that Paxlovid (nirmatrelvir/ritonavir) significantly reduces the risk of COVID-19-related hospitalization in high-risk adults. The analysis, conducted across multiple healthcare systems, demonstrated a 62% reduction in hospitalization risk among patients who received Paxlovid within five days of symptom onset. The study included over 100,000 patients and represents one of the largest real-world analyses of Paxlovid effectiveness to date. These findings reinforce the importance of early treatment with Paxlovid for individuals at high risk of severe COVID-19 outcomes. Pfizer continues to monitor the effectiveness of Paxlovid against emerging SARS-CoV-2 variants.